Stockholmbased Redwood Pharma participated in the BioStock Investor Meeting in September where CEO Martin Vidaeus presented the company’s work. Afterwards, BioStock had the chance to interview Vidaeus who told us more about Redwood Pharma’s projects RP501 and RP101, aimed at the treatment of dry eyes.

See the interview with Redwood Pharma’s CEO Martin Vidaeus below.

Please note that the interview was recorded before the news that Redwood Pharma’s board of directors has resolved on a share issue of approximately 33,2 MSEK.  

Prenumerera på BioStocks nyhetsbrev